ArticleAsian Pacific journal of cancer prevention : APJCP2025
Quantifying the Contribution of Viral Hepatitis Control Policies and Improvement of Hepatitis C Treatment in Japan during 2000-2030 based on Simulation Modelling.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- International trends in cancer mortality revisited: Japan's site-specific progress and remaining challenges until 2024.Japanese journal of clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major causes of hepatocellular carcinoma (HCC) in Japan. The Japanese government has implemented various countermeasures since the early 2000s, including expanded screening and effective antiviral treatments. Evaluating the long-term impact of these policies is essential for guiding future strategies.
methodsWe developed a Markov model-based simulation to estimate the annual transition of HBV/HCV carriers, disease progression, and HCC-related outcomes in Japan from 2000 to 2030. Five policy scenarios were set, reflecting the implementation stages of national countermeasures. A sensitivity analysis was also conducted by varying post-2020 hospital visit rates, the proportion of DAA treatment in chronic hepatitis/cirrhosis, and HCC mortality rates.
resultsThe simulation predicted a reduction in HCV carriers from 480,000 in Scenario 1 (no intervention) to 270,000 in Scenario 5 (reflecting 2020 policies). The number of chronic hepatitis and cirrhosis patients also declined significantly, mainly due to the introduction of direct-acting antivirals (DAAs). All scenarios showed a downward trend in new HCC cases and mortality; the decline was most pronounced in Scenario 5. Under Scenario 5, age-adjusted HCC mortality in 2030 was reduced by 53% compared to 2015 level. Sensitivity analysis revealed that variations in hospital visit rates, treatment proportions, and HCC mortality could lead to HCC deaths in 2030 ranging from 5,797 to 7,065. DISCUSSION: Our findings suggest that sustained hepatitis countermeasures and the introduction of DAAs have significantly contributed to the decline in HCV-related disease burden in Japan. Simulation modeling provides a useful framework for evaluating past policies and projecting future outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.